AbCellera Biologics (ABCL) Other Accumulated Expenses (2020 - 2023)

AbCellera Biologics (ABCL) has 4 years of Other Accumulated Expenses data on file, last reported at $3.1 million in Q3 2023.

• Quarterly Other Accumulated Expenses fell 82.64% year-over-year to $3.1 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $3.1 million (down 82.64% YoY) and the FY2022 annual result came in at $19.3 million, down 14.04% from the prior year.
• Other Accumulated Expenses held at $3.1 million in Q3 2023, from $3.1 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $50.6 million in Q2 2022 to a low of $595000.0 in Q3 2021.
• A 4-year average of $19.7 million and a median of $19.7 million in 2021 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses jumped 2895.29% — and 2023, when it tumbled 93.88%.
• Tracing ABCL's Other Accumulated Expenses over 4 years: stood at $27.1 million in 2020, then fell by 17.08% to $22.5 million in 2021, then slipped by 14.04% to $19.3 million in 2022, then sank by 84.01% to $3.1 million in 2023.
• The last three Other Accumulated Expenses figures came in at $3.1 million (Q3 2023), $3.1 million (Q2 2023), and $3.1 million (Q1 2023), per Business Quant data.